Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Consensus PT from Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given a consensus rating of “Buy” by the ten analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $21.29.

A number of research firms have issued reports on STOK. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, Chardan Capital started coverage on Stoke Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $24.00 target price on the stock.

Stoke Therapeutics Price Performance

Shares of STOK stock opened at $8.96 on Monday. The stock’s fifty day moving average price is $12.05 and its 200 day moving average price is $13.11. Stoke Therapeutics has a 1-year low of $4.09 and a 1-year high of $17.58. The company has a market cap of $474.58 million, a price-to-earnings ratio of -4.27 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, equities research analysts anticipate that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the transaction, the chief executive officer now owns 68,671 shares in the company, valued at $877,615.38. The trade was a 8.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 13,945 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the transaction, the insider now owns 47,332 shares in the company, valued at $604,902.96. This represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,849 shares of company stock worth $809,421. Corporate insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Lynx1 Capital Management LP raised its holdings in shares of Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after acquiring an additional 1,488,371 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after purchasing an additional 1,123,500 shares during the last quarter. Logos Global Management LP purchased a new position in Stoke Therapeutics in the 2nd quarter valued at $14,186,000. Marshall Wace LLP boosted its stake in Stoke Therapeutics by 550.1% during the 2nd quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock worth $15,686,000 after purchasing an additional 982,451 shares during the last quarter. Finally, RTW Investments LP grew its holdings in shares of Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after buying an additional 427,447 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.